ProCE Banner Activity

BRIGHTE: Wk 96 Results From Phase III Study of Fostemsavir + OBT in Heavily Treatment–Experienced Patients Failing Current ART

Slideset Download
Conference Coverage
Virologic suppression rates and CD4+ cell counts continued to improve through Week 96 in this difficult-to-treat population receiving fostemsavir plus optimized background therapy.

Released: July 24, 2019

Share

Provided by

Provided by the USF Health
ProCE Banner

Supporters

Educational grant provided by:

Gilead

ViiV Healthcare

Partners

IAS 2018

ProCE Banner

IAS 2019

ProCE Banner